60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

Core Insights - 60 Degrees Pharmaceuticals, Inc. has announced a partnership with GoodRx to provide savings of up to 30% on ARAKODA (tafenoquine) for eligible consumers [1][10] - ARAKODA is the only FDA-approved, once-weekly malaria prevention medication available in the U.S. market, making it a preferred choice for travelers to malaria-endemic regions [2][6] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for ARAKODA in 2018 [19] - The company is headquartered in Washington, D.C., and has a subsidiary in Australia, with ARAKODA commercially available in both countries [19] Product Information - ARAKODA (tafenoquine) is indicated for malaria prophylaxis in patients aged 18 and older and has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [7][8] - The medication was discovered by the Walter Reed Army Institute of Research and has undergone extensive safety assessments in clinical trials [5][6] Partnership Details - The collaboration with GoodRx aims to lower out-of-pocket costs for patients and expand the marketing reach of ARAKODA, making it accessible at over 70,000 pharmacies nationwide [10][4] - Eligible patients can access a low self-pay price for ARAKODA through GoodRx starting February 2, 2026 [4][10]